尿酸前体肌苷对早期帕金森病进展的影响:SURE-PD3随机临床试验
这项随机双盲安慰剂对照3期试验纳入298例血清尿酸低于5.8 mg/dL的早期帕金森病患者,评估口服肌苷提升尿酸至7.1-8.0 mg/dL能否延缓疾病进展。
要点
- 肌苷组血清尿酸持续升高约2.03 mg/dL,安慰剂组仅变化0.01 mg/dL。
- 肌苷组严重不良事件较少(7.4 vs 13.1/100患者年),但肾结石更多(7.0 vs 1.4/100患者年)。
核心结论
- 在早期帕金森病患者中,肌苷治疗与安慰剂相比未显著改变临床疾病进展速率。
- 研究结果不支持使用肌苷治疗早期帕金森病。
研究设计与样本
- 随机、双盲、安慰剂对照的3期试验,在美国58个中心开展。
- 298例早期帕金森病患者随机分配至肌苷组(n=149)或安慰剂组(n=149),治疗最长2年。
- 入组条件包括尚未需要多巴胺能药物治疗、纹状体多巴胺转运体缺陷、血清尿酸低于人群中位数(<5.8 mg/dL)。
主要发现
- 肌苷组血清尿酸较基线4.6 mg/dL持续升高2.03 mg/dL(增幅44%),安慰剂组变化0.01 mg/dL,差异2.02 mg/dL(95%CI 1.85-2.19,P<.001)。
- 包括多巴胺转运体结合丢失在内的次要疗效结局均无显著差异。
- 肌苷组严重不良事件发生率为7.4/100患者年,安慰剂组为13.1/100患者年;肾结石发生率为7.0 vs 1.4/100患者年。
临床怎么用
- 不推荐使用肌苷提升尿酸来延缓早期帕金森病进展。
- 对早期帕金森病患者使用肌苷时需关注肾结石风险增加。
局限性
- 研究基于预设的无效性中期分析提前终止。
- 273例(92%)随机参与者完成研究,随访至2019年6月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Urate elevation, despite associations with crystallopathic, cardiovascular, and metabolic disorders, has been pursued as a potential disease-modifying strategy for Parkinson disease (PD) based on convergent biological, epidemiological, and clinical data. OBJECTIVE: To determine whether sustained urate-elevating treatment with the urate precursor inosine slows early PD progression. DESIGN, PARTICIPANTS, AND SETTING: Randomized, double-blind, placebo-controlled, phase 3 trial of oral inosine treatment in early PD. A total of 587 individuals consented, and 298 with PD not yet requiring dopaminergic medication, striatal dopamine transporter deficiency, and serum urate below the population median concentration (<5.8 mg/dL) were randomized between August 2016 and December 2017 at 58 US sites, and were followed up through June 2019. INTERVENTIONS: Inosine, dosed by blinded titration to increase serum urate concentrations to 7.1-8.0 mg/dL (n = 149) or matching placebo (n = 149) for up to 2 years. MAIN OUTCOMES AND MEASURES: The primary outcome was rate of change in the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS; parts I-III) total score (range, 0-236; higher scores indicate greater disability; minimum clinically important difference of 6.3 points) prior to dopaminergic drug therapy initiation. Secondary outcomes included serum urate to measure target engagement, adverse events to measure safety, and 29 efficacy measures of disability, quality of life, cognition, mood, autonomic function, and striatal dopamine transporter binding as a biomarker of neuronal integrity. RESULTS: Based on a prespecified interim futility analysis, the study closed early, with 273 (92%) of the randomized participants (49% women; mean age, 63 years) completing the study. Clinical progression rates were not significantly different between participants randomized to inosine (MDS-UPDRS score, 11.1 [95% CI, 9.7-12.6] points per year) and placebo (MDS-UPDRS score, 9.9 [95% CI, 8.4-11.3] points per year; difference, 1.26 [95% CI, -0.59 to 3.11] points per year; P = .18). Sustained elevation of serum urate by 2.03 mg/dL (from a baseline level of 4.6 mg/dL; 44% increase) occurred in the inosine group vs a 0.01-mg/dL change in serum urate in the placebo group (difference, 2.02 mg/dL [95% CI, 1.85-2.19 mg/dL]; P<.001). There were no significant differences for secondary efficacy outcomes including dopamine transporter binding loss. Participants randomized to inosine, compared with placebo, experienced fewer serious adverse events (7.4 vs 13.1 per 100 patient-years) but more kidney stones (7.0 vs 1.4 stones per 100 patient-years). CONCLUSIONS AND RELEVANCE: Among patients recently diagnosed as having PD, treatment with inosine, compared with placebo, did not result in a significant difference in the rate of clinical disease progression. The findings do not support the use of inosine as a treatment for early PD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02642393.
引用
- Schwarzschild MA, Ascherio A, Casaceli C, et al. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA. 2021. PMID: 34519802. doi:10.1001/jama.2021.10207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。